News Release

2014.10.23
Notification of the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
2014.10.20
Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Actavis
2014.10.09
FY02/2015 Q2 Results Earnings Release Presentation
2014.10.02
Notice of Revision of Financial Forecast
2014.09.26
Noven Pharmaceuticals, Inc. press release :Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® (Estradiol Transdermal System)
2014.08.05
Notice of Dissolution of US Equity Method Affiliate Vivelle Ventures LLC (d/b/a Novogyne Pharmaceuticals)
2014.07.10
FY02/2015 Q1 Results Earnings Release Presentation
2014.07.02
Notification of the Noven Pharmaceuticals, Inc. assigns rights for Lithobid® (lithium carbonate tablets)
2014.06.20
Notification of approval of the additional indication for chronic pain of the transdermal long-acting pain relief patch FENTOS® TAPE (development code: HFT-290)
2014.05.29
Announcement of 2014 National Commendation for Invention “The Prize of the Commissioner of Japan PatentOffice” – For Invention of anti-inflammatory analgesic patch superior in percutaneous absorbability –
2014.05.13
5th Medium-term Management Plan for FY2014-2018
2014.05.13
Notice Concerning the Establishment of the 5th Medium-term Management Plan
2014.05.07
Press Release related to the results of Phase II clinical study on HP-3060 in Japan (a transdermal system for the treatment of allergic rhinitis)
2014.04.24
Notification on the commencement of Phase I clinical trial of HP-3070 in the United States (a transdermal tape formulation for the treatment of schizophrenia)
2014.04.17
Noven Pharmaceuticals, Inc. press release :Noven announces settlement of LIDODERM® patent litigation
2014.04.10
FY02/2014 Q4 Results Earnings Release Presentation
2014.04.10
Announcement of Dividend of Surplus in the Fiscal Year Ended February 2014 (112th Fiscal Year)
2014.02.21
Notification of approval of additional ‘indication’ and ‘dosage and administration’ of the estradiol transdermal patch Estrana® Tape 0.72 mg
2014.02.05
Notification of the results of Phase II clinical study of HP-3000 in Japan (a transdermal drug for the treatment of Parkinson’s disease)
2014.01.14
Noven Pharmaceuticals, Inc. press release :Noven Enters Co-Promotion Agreement with Shionogi for Brisdelleā„¢ (Paroxetine) Capsules
2014.01.09
FY02/2014 Q3 Results Earnings Release Presentation

PAGETOP